Saxenda®

Dosage

£0.00

Our medical team are based in the UK and registered with the General Medical Council and General Pharmaceutical Council.

Active Ingredient

Liraglutide

Indications

For obesity (BMI ≥30) or overweight (BMI ≥27) with conditions

Effectiveness

5-10% body weight reduction

Warnings

Avoid if history of thyroid cancer or pancreatitis

Mode of Action

GLP-1 receptor agonist; reduces hunger & increases fullness

Dosage

Daily injection, up to 3 mg

Side Effects

Nausea, vomiting, diarrhea, constipation

Lifestyle

Combine with diet and exercise for best results

Features	Mounjaro® Injectable Pen	Wegovy® Injectable Pen	Saxenda® Injectable Pen
Active Ingredient	Tirzepatide	Semaglutide	Liraglutide
Mechanism of Action	GLP-1 and GIP receptor agonist	GLP-1 receptor agonist	GLP-1 receptor agonist
Administration	Weekly injection	Weekly injection	Daily injection
Dosage	Varies by patient, typically starting low	Varies, typically starting at 0.25 mg	Varies, starting at 0.6 mg
Effect on Appetite	Significantly reduces appetite and cravings	Reduces appetite and increases satiety	Reduces appetite and increases satiety
Average Weight Loss	Up to 20% body weight reduction	Up to 15% body weight reduction	Significant weight reduction
Side Effects	Nausea, vomiting, diarrhoea, constipation	Nausea, vomiting, diarrhoea, constipation	Nausea, diarrhoea, constipation, hypoglycemia
Approval	FDA-approved for weight loss	FDA-approved for weight loss	FDA-approved for weight loss
Suitable For	Adults with BMI ≥30 or ≥27 with comorbidities	Adults with BMI ≥30 or ≥27 with comorbidities	Adults with BMI ≥30 or ≥27 with comorbidities

Skip GP and pharmacy trips with a 2-minute online assessment.

Choose an effective weight loss treatment tailored for you.

Receive your treatment delivered in discreet packaging to your home.